Massive reforms are changing the world’s fastest growing market. However, alongside rapid growth, China’s industry is facing major disruptions in the operating environment as the country implements a three-year $124 billion health reform that represents just the first wave of systemic changes scheduled to take place over the next decade.Buyer characteristics, the product selection process, pricing, distribution channels, customer geographics and demographics – all of these will be profoundly different in the environment that is emerging under the new health reforms. Industry decision-makers cannot afford to ignore how these changes will affect the country.
“China: Health Reforms and the Future of the Pharmaceutical Market” is a just-released report from VOI Consulting. The report explains China’s pharmaceutical market and contains in-depth coverage of health reforms, the impact they will have on the operating environment, and strategies that will allow companies to capitalize on opportunities and minimize risks.
Details of China’s reforms are presented, plus a review of:
- How the money will be spent and who will be affected
- The selection process for the national formulary
- Current and emerging buyer profiles and market segmentation strategies.
- The fastest growing distribution channels
- The rising importance of the mid-sized cities and rural areas
- How changes in the price control regime will affect margins and customer incentives
- How other leading companies are adapting to the changes
- Developed Markets
- Asia Pacific: Australia, Japan, South Korea, New Zealand
- Europe: Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, UK, Switzerland
- Middle East: Israel
- North America: Canada, US
- Asia Pacific: China, India, Indonesia, Taiwan, Thailand
- Europe: Czech Republic, Hungary, Poland, Romania, Russia
- Latin America: Argentina, Brazil, Chile, Mexico, Venezuela
- Middle East/Africa: Egypt, Turkey, South Africa
No comments:
Post a Comment